FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099814026> ?p ?o ?g. }

• W2099814026 endingPage "5821" @default.
• W2099814026 startingPage "5814" @default.
• W2099814026 abstract "Dengue disease is a major public health problem across the Asia-Pacific region for which there is no licensed vaccine or treatment. We evaluated the safety and immunogenicity of Phase III lots of a candidate vaccine (CYD-TDV) in children in Malaysia.In this observer-blind, placebo-controlled, Phase III study, children aged 2-11 years were randomized (4:1) to receive CYD-TDV or placebo at 0, 6 and 12 months. Primary endpoints included assessment of reactogenicity following each dose, adverse events (AEs) and serious AEs (SAEs) reported throughout the study, and immunogenicity expressed as geometric mean titres (GMTs) and distribution of dengue virus (DENV) neutralizing antibody titres.250 participants enrolled in the study (CYD-TDV: n=199; placebo: n=51). There was a trend for reactogenicity to be higher with CYD-TDV than with placebo post-dose 1 (75.4% versus 68.6%) and post-dose 2 (71.6% versus 62.0%) and slightly lower post-dose 3 (57.9% versus 64.0%). Unsolicited AEs declined in frequency with each subsequent dose and were similar overall between groups (CYD-TDV: 53.8%; placebo: 49.0%). Most AEs were of Grade 1 intensity and were transient. SAEs were reported by 5.5% and 11.8% of participants in the CYD-TDV and placebo groups, respectively. No deaths were reported. Baseline seropositivity against each of the four DENV serotypes was similar between groups, ranging from 24.0% (DENV-4) to 36.7% (DENV-3). In the CYD-TDV group, GMTs increased post-dose 2 for all serotypes compared with baseline, ranging from 4.8 (DENV-1) to 8.1-fold (DENV-3). GMTs further increased post-dose 3 for DENV-1 and DENV-2. Compared with baseline, individual titre increases ranged from 6.1-fold (DENV-1) to 7.96-fold (DENV-3).This study demonstrated a satisfactory safety profile and a balanced humoral immune response against all four DENV serotypes for CYD-TDV administered via a three-dose regimen to children in Malaysia." @default.
• W2099814026 created "2016-06-24" @default.
• W2099814026 creator A5003232606 @default.
• W2099814026 creator A5007158791 @default.
• W2099814026 creator A5017151124 @default.
• W2099814026 creator A5038262133 @default.
• W2099814026 creator A5041092944 @default.
• W2099814026 creator A5063423263 @default.
• W2099814026 creator A5070153675 @default.
• W2099814026 creator A5077925330 @default.
• W2099814026 date "2013-12-01" @default.
• W2099814026 modified "2023-10-17" @default.
• W2099814026 title "Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study" @default.
• W2099814026 cites W1970660384 @default.
• W2099814026 cites W1980444528 @default.
• W2099814026 cites W1989767365 @default.
• W2099814026 cites W1996416492 @default.
• W2099814026 cites W2006146542 @default.
• W2099814026 cites W2017258497 @default.
• W2099814026 cites W2023010141 @default.
• W2099814026 cites W2034093511 @default.
• W2099814026 cites W2053017525 @default.
• W2099814026 cites W2065599363 @default.
• W2099814026 cites W2086448648 @default.
• W2099814026 cites W2097288560 @default.
• W2099814026 cites W2104989660 @default.
• W2099814026 cites W2134850550 @default.
• W2099814026 cites W2137591261 @default.
• W2099814026 cites W2155660565 @default.
• W2099814026 cites W2164404874 @default.
• W2099814026 cites W2171207651 @default.
• W2099814026 cites W2317607320 @default.
• W2099814026 doi "https://doi.org/10.1016/j.vaccine.2013.10.013" @default.
• W2099814026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24135573" @default.
• W2099814026 hasPublicationYear "2013" @default.
• W2099814026 type Work @default.
• W2099814026 sameAs 2099814026 @default.
• W2099814026 citedByCount "41" @default.
• W2099814026 countsByYear W20998140262014 @default.
• W2099814026 countsByYear W20998140262015 @default.
• W2099814026 countsByYear W20998140262016 @default.
• W2099814026 countsByYear W20998140262017 @default.
• W2099814026 countsByYear W20998140262018 @default.
• W2099814026 countsByYear W20998140262019 @default.
• W2099814026 countsByYear W20998140262020 @default.
• W2099814026 countsByYear W20998140262021 @default.
• W2099814026 countsByYear W20998140262022 @default.
• W2099814026 countsByYear W20998140262023 @default.
• W2099814026 crossrefType "journal-article" @default.
• W2099814026 hasAuthorship W2099814026A5003232606 @default.
• W2099814026 hasAuthorship W2099814026A5007158791 @default.
• W2099814026 hasAuthorship W2099814026A5017151124 @default.
• W2099814026 hasAuthorship W2099814026A5038262133 @default.
• W2099814026 hasAuthorship W2099814026A5041092944 @default.
• W2099814026 hasAuthorship W2099814026A5063423263 @default.
• W2099814026 hasAuthorship W2099814026A5070153675 @default.
• W2099814026 hasAuthorship W2099814026A5077925330 @default.
• W2099814026 hasBestOaLocation W20998140261 @default.
• W2099814026 hasConcept C126322002 @default.
• W2099814026 hasConcept C142724271 @default.
• W2099814026 hasConcept C159654299 @default.
• W2099814026 hasConcept C168563851 @default.
• W2099814026 hasConcept C197934379 @default.
• W2099814026 hasConcept C203014093 @default.
• W2099814026 hasConcept C204787440 @default.
• W2099814026 hasConcept C27081682 @default.
• W2099814026 hasConcept C2777704310 @default.
• W2099814026 hasConcept C2779308166 @default.
• W2099814026 hasConcept C2779635636 @default.
• W2099814026 hasConcept C2780868878 @default.
• W2099814026 hasConcept C533803919 @default.
• W2099814026 hasConcept C71924100 @default.
• W2099814026 hasConceptScore W2099814026C126322002 @default.
• W2099814026 hasConceptScore W2099814026C142724271 @default.
• W2099814026 hasConceptScore W2099814026C159654299 @default.
• W2099814026 hasConceptScore W2099814026C168563851 @default.
• W2099814026 hasConceptScore W2099814026C197934379 @default.
• W2099814026 hasConceptScore W2099814026C203014093 @default.
• W2099814026 hasConceptScore W2099814026C204787440 @default.
• W2099814026 hasConceptScore W2099814026C27081682 @default.
• W2099814026 hasConceptScore W2099814026C2777704310 @default.
• W2099814026 hasConceptScore W2099814026C2779308166 @default.
• W2099814026 hasConceptScore W2099814026C2779635636 @default.
• W2099814026 hasConceptScore W2099814026C2780868878 @default.
• W2099814026 hasConceptScore W2099814026C533803919 @default.
• W2099814026 hasConceptScore W2099814026C71924100 @default.
• W2099814026 hasIssue "49" @default.
• W2099814026 hasLocation W20998140261 @default.
• W2099814026 hasLocation W20998140262 @default.
• W2099814026 hasOpenAccess W2099814026 @default.
• W2099814026 hasPrimaryLocation W20998140261 @default.
• W2099814026 hasRelatedWork W1996624180 @default.
• W2099814026 hasRelatedWork W2033265148 @default.
• W2099814026 hasRelatedWork W2121368175 @default.
• W2099814026 hasRelatedWork W2171301561 @default.
• W2099814026 hasRelatedWork W2408404678 @default.
• W2099814026 hasRelatedWork W2416138822 @default.
• W2099814026 hasRelatedWork W3212313869 @default.

• next